Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

14.11.24 19:21 Uhr

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.Weiter zum vollständigen Artikel bei MarketWatch

Quelle: MarketWatch

Nachrichten zu View Inc Registered Shs -A-